Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells $155,279.00 in Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $50.09, for a total transaction of $155,279.00. Following the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $2,116,102.14. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total value of $155,589.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total value of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.01, for a total value of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total transaction of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The stock was sold at an average price of $39.25, for a total transaction of $353,250.00.

RxSight Price Performance

Shares of RXST opened at $50.03 on Friday. RxSight, Inc. has a fifty-two week low of $20.66 and a fifty-two week high of $66.54. The business has a 50-day moving average of $52.13 and a 200 day moving average of $53.82.

RxSight (NASDAQ:RXST) last issued its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The firm had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. During the same quarter last year, the business earned ($0.40) earnings per share. The company’s quarterly revenue was up 67.6% on a year-over-year basis. On average, research analysts expect that RxSight, Inc. will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Marshall Wace LLP purchased a new stake in shares of RxSight during the second quarter worth $19,512,000. Driehaus Capital Management LLC raised its stake in shares of RxSight by 74.9% during the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after purchasing an additional 302,367 shares during the period. Baillie Gifford & Co. lifted its holdings in RxSight by 438.8% during the 2nd quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock worth $21,554,000 after purchasing an additional 291,733 shares in the last quarter. William Blair Investment Management LLC bought a new position in RxSight in the 2nd quarter worth about $14,942,000. Finally, M&G Plc purchased a new position in RxSight during the 1st quarter valued at about $7,354,000. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on RXST. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Stifel Nicolaus reduced their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. BTIG Research lifted their target price on RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Wells Fargo & Company reduced their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Finally, Oppenheimer lowered their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, RxSight has a consensus rating of “Buy” and an average price target of $60.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.